An Open, Non-randomized Pilot Study on the Effect of Preservative Free Tafluprost (Saflutan® Augentropfen) in Patients With Ocular Hypertension or Primary Open Angle Glaucoma With an Uncontrolled Intraocular Pressure of 30 mmHg and More

Inclusion Criteria: * Men and women aged over 18 years * Diagnosed primary open angle glaucoma and an IOP of 30mmHg or more in at least 1 eye at visit 1 at 8 am * Patients with ocular hypertension as defined as an IOP of 30mmHg or more and normal findings in the visual field and the optic nerve head Exclusion Criteria: * Participation in a clinical trial in the 3 weeks before the screening visit * Severe visual field loss as defined as an MD of -15 or worse * Symptoms of a clinically relevant illness in the 3 weeks before the first study day * Presence or history of a severe medical condition that will interfere with the study aim as judged by the clinical investigator * Presence or history of a severe ocular condition that will interfere with the study aim as judged by the clinical investigator * Wearing of contact lenses * Topical treatment with any ophthalmic drug in the 4 weeks preceding the study except glaucoma medication or topical lubricants * Ocular infection * Ocular surgery in the 6 months preceding the study * Pregnancy, planned pregnancy or lactating * Contraindication against the use of topical prostaglandin therapy